Glaukos Corp
$ 119.17
-1.03%
24 Feb - close price
- Market Cap 6,924,900,000 USD
- Current Price $ 119.17
- High / Low $ 122.48 / 118.77
- Stock P/E N/A
- Book Value 11.41
- EPS -3.28
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.26 %
- 52 Week High 130.23
- 52 Week Low 73.16
About
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California.
Analyst Target Price
$134.79
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-17 | 2025-10-29 | 2025-07-30 | 2025-04-29 | 2025-02-19 | 2024-11-04 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-11-01 | 2023-08-02 | 2023-05-03 |
| Reported EPS | -0.28 | -0.16 | -0.24 | -0.22 | -0.4 | -0.28 | -0.52 | -0.7 | -0.63 | -0.5 | -0.55 | -0.59 |
| Estimated EPS | -0.2131 | -0.26 | -0.26 | -0.3556 | -0.3885 | -0.48 | -0.51 | -0.57 | -0.55 | -0.55 | -0.55 | -0.58 |
| Surprise | -0.0669 | 0.1 | 0.02 | 0.1356 | -0.0115 | 0.2 | -0.01 | -0.13 | -0.08 | 0.05 | 0 | -0.01 |
| Surprise Percentage | -31.3937% | 38.4615% | 7.6923% | 38.1327% | -2.9601% | 41.6667% | -1.9608% | -22.807% | -14.5455% | 9.0909% | 0% | -1.7241% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.1847 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GKOS
2026-02-23 13:36:11
Glaukos Corporation (NYSE: GKOS) showed strong performance in Q4 2025, with a 38.1% revenue growth, leading to its inclusion as a significant contributor in The Brown Capital Management Small Company Fund's investor letter. The company's ophthalmic products, particularly the iDose implant for glaucoma treatment, drove a 57% year-over-year increase in U.S. glaucoma franchise sales. Glaukos also received FDA approval for Epioxa and provided optimistic revenue guidance for 2026, indicating continued growth.
2026-02-23 10:59:39
GLAUKOS Corp (GKOS) released its annual 10-K report, showcasing significant financial and operational growth, including a 32% increase in net sales to $507.4 million driven by iDose TR sales. The report details strategic initiatives like the acquisition of Mobius Therapeutics and FDA approval for Epioxa, alongside challenges such as increased net loss, market adjustments, and global economic risks. The company plans future expansion with a new R&D and manufacturing facility and aims to leverage existing cash for operations.
2026-02-23 10:22:01
Glaukos Corporation (GKOS) reported strong fourth-quarter and full-year 2025 sales, yet posted a net loss due to a significant intangible asset impairment. Despite ongoing losses, the company issued a robust 2026 sales guidance of US$600 million to US$620 million, driven by its expanding ophthalmic portfolio including new product launches. This positive outlook has led to a 9.9% increase in its stock price, but investors are still watching for the company's path to profitability.
2026-02-21 07:31:25
Wall Street Zen downgraded Glaukos (NYSE:GKOS) from "buy" to "hold," despite a broader analyst consensus remaining a "Moderate Buy" with an average target price of $133.69. This downgrade follows Glaukos reporting mixed Q4 results, missing EPS estimates but exceeding revenue expectations, with analysts projecting a negative EPS of -1.08 for the current year. The report also highlights significant insider selling, including the CEO reducing his stake by nearly 55%.
2026-02-19 01:56:54
Stifel maintained its Buy rating and $160.00 price target on Glaukos Corporation (NYSE:GKOS) shares, citing positive developments for the company’s iDose and Epioxa products. The firm anticipates sequential growth for iDose in 2026 and notes Epioxa system placements are exceeding expectations, with favorable payer coverage. Despite a high Price/Book ratio, analysts express growing confidence in Glaukos's future performance, further bolstered by the FDA's recent approval for re-administration of iDose TR.
2026-02-19 00:57:35
Needham has reaffirmed its "Buy" rating for Glaukos (GKOS) and increased its price target to $127. This adjustment reflects a continuous positive trend from various analysts, who have consistently maintained "Buy" or "Overweight" ratings and have raised price targets for the company throughout January and February 2026. Glaukos, an ophthalmic pharmaceutical and medical technology company, specializes in developing therapies and products for glaucoma, corneal disorders, and retinal diseases, with strong market analyst support and an "Outperform" consensus.
